Description: Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Home Page: greenwichlifesciences.com
GLSI Technical Analysis
Building 14
Stafford,
TX
77477
United States
Phone:
832 819 3232
Officers
Name | Title |
---|---|
Mr. Snehal S. Patel | CEO, CFO & Director |
Mr. Eric Rothe | Founder & Independent Director |
Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director |
Dr. Jaye L. Thompson Ph.D. | VP of Clinical & Regulatory Affairs |
Dr. Christine T. Fischette Ph.D. | VP of Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 10.9471 |
Price-to-Sales TTM: | 0 |
IPO Date: | 2020-09-25 |
Fiscal Year End: | December |
Full Time Employees: | 3 |